阿替利珠单抗联合卡铂依托泊苷一线治疗广泛期小细胞肺癌的更新总生存及PD-L1亚组分析(IMpower133)
IMpower133研究为随机双盲I/III期试验,比较阿替利珠单抗或安慰剂联合卡铂+依托泊苷一线治疗广泛期小细胞肺癌。无论PD-L1免疫组化或bTMB状态,患者均从阿替利珠单抗联合治疗中获益。
要点
- 阿替利珠单抗联合CP/ET一线治疗ES-SCLC更新分析显示OS持续获益,中位OS 12.3 vs 10.3个月。
- 18个月生存率阿替利珠单抗组34.0%,安慰剂组21.0%。
- 探索性分析表明治疗获益不依赖于PD-L1免疫组化或bTMB状态。
核心结论
- 在更新分析中,阿替利珠单抗联合卡铂+依托泊苷一线治疗广泛期小细胞肺癌持续显示总生存改善且安全性可耐受,确认该方案为新标准治疗。
研究设计与样本
- IMpower133为随机双盲I/III期研究,患者按1:1随机接受阿替利珠单抗联合卡铂+依托泊苷或安慰剂联合卡铂+依托泊苷治疗。
- 阿替利珠单抗组201例,安慰剂组202例;PD-L1检测非入组必需。
主要发现
- 更新分析时中位OS随访22.9个月,共发生302例死亡。
- 18个月时阿替利珠单抗组34.0%患者存活,安慰剂组21.0%患者存活。
- 无论PD-L1免疫组化或bTMB状态如何,患者均从阿替利珠单抗联合治疗中获益。
临床怎么用
- 对于未经治疗的广泛期小细胞肺癌患者,可考虑阿替利珠单抗联合卡铂+依托泊苷作为一线治疗选择。
- 治疗获益不依赖于PD-L1免疫组化或bTMB状态,无需依据这些生物标志物筛选患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: IMpower133 (ClinicalTrials.gov identifier: NCT02763579), a randomized, double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-ligand 1 [PD-L1]) to carboplatin plus etoposide (CP/ET) for first-line (1L) treatment of extensive-stage small-cell lung cancer (ES-SCLC) resulted in significant improvement in overall survival (OS) and progression-free survival (PFS) versus placebo plus CP/ET. Updated OS, disease progression patterns, safety, and exploratory biomarkers (PD-L1, blood-based tumor mutational burden [bTMB]) are reported. PATIENTS AND METHODS: Patients with untreated ES-SCLC were randomly assigned 1:1 to receive four 21-day cycles of CP (area under the curve 5 mg per mL/min intravenously [IV], day 1) plus ET (100 mg/m2 IV, days 1-3) with atezolizumab (1,200 mg IV, day 1) or placebo, and then maintenance atezolizumab or placebo until unacceptable toxicity, disease progression, or loss of clinical benefit. Tumor specimens were collected; PD-L1 testing was not required for enrollment. The two primary end points, investigator-assessed PFS and OS, were statistically significant at the interim analysis. Updated OS and PFS and exploratory biomarker analyses were conducted. RESULTS: Patients received atezolizumab plus CP/ET (n = 201) or placebo plus CP/ET (n = 202). At the updated analysis, median follow-up for OS was 22.9 months; 302 deaths had occurred. Median OS was 12.3 and 10.3 months with atezolizumab plus CP/ET and placebo plus CP/ET, respectively (hazard ratio, 0.76; 95% CI, 0.60 to 0.95; descriptive P = .0154). At 18 months, 34.0% and 21.0% of patients were alive in atezolizumab plus CP/ET and placebo plus CP/ET arms, respectively. Patients derived benefit from the addition of atezolizumab, regardless of PD-L1 immunohistochemistry or bTMB status. CONCLUSION: Adding atezolizumab to CP/ET as 1L treatment for ES-SCLC continued to demonstrate improved OS and a tolerable safety profile at the updated analysis, confirming the regimen as a new standard of care. Exploratory analyses demonstrated treatment benefit independent of biomarker status.
引用
- Liu SV, Reck M, Mansfield AS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021. PMID: 33439693. doi:10.1200/JCO.20.01055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。